EMEA-002573-PIP01-19 - paediatric investigation plan

EGFR-cMET bispecific antibody

Key facts

• Active Substance:
  EGFR-cMET bispecific antibody
• Therapeutic area:
  Oncology
• Decision number:
  P/0289/2019
• PIP number:
  EMEA-002573-PIP01-19
• Pharmaceutical form(s):
  • Concentrate for solution for infusion
  • Solution for injection
• Condition(s) / indication(s):
  Treatment of lung carcinoma
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  16/08/2019

Decision

P/0289/2019: EMA decision of 16 August 2019 on the granting of a product specific waiver for EGFR-cMET bispecific antibody (EMEA-002573-PIP01-19)

AdoptedReference Number: EMA/444280/2019